
ENTX
Entera Bio Ltd
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.910
Open
1.910
VWAP
--
Vol
37.73K
Mkt Cap
84.54M
Low
1.850
Amount
--
EV/EBITDA(TTM)
--
Total Shares
36.03M
EV
71.97M
EV/OCF(TTM)
--
P/S(TTM)
--
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Show More
Valuation Metrics
The current forward P/E ratio for Entera Bio Ltd (ENTX.O) is -3.38, compared to its 5-year average forward P/E of -3.98. For a more detailed relative valuation and DCF analysis to assess Entera Bio Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-3.98
Current PE
-3.38
Overvalued PE
-1.57
Undervalued PE
-6.39
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
457.94
Current PS
0.00
Overvalued PS
1047.99
Undervalued PS
-132.12
Financials
Annual
Quarterly
FY2025Q1
42.00K
Total Revenue
FY2025Q1
YoY :
+24.30%
-2.56M
Operating Profit
FY2025Q1
YoY :
+27.27%
-2.57M
Net Income after Tax
FY2025Q1
YoY :
+20.00%
-0.06
EPS - Diluted
FY2025Q1
YoY :
-24.17%
-1.41M
Free Cash Flow
FY2025Q1
0.00
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
-6.11K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ENTX News & Events
Events Timeline
2025-06-26 (ET)
2025-06-26
08:15:58
Entera Bio announces data for EB613 to be presented at ASBMR 2025

2025-06-25 (ET)
2025-06-25
08:06:40
Opko Health, Entera Bio say OPK-88006 data selected for ENDO 2025

2025-04-15 (ET)
2025-04-15
08:37:17
Entera Bio announces highlights from presentation at WCO-IFO-ESCEO on EB613

Sign Up For More Events
Sign Up For More Events
News
5.0
07-08GlobenewswireOPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
1.0
06-29Yahoo FinanceOPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025
9.0
06-26NewsfilterEntera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
Sign Up For More News
People Also Watch
FAQ

What is Entera Bio Ltd (ENTX) stock price today?
The current price of ENTX is 1.86 USD — it has decreased -2.62 % in the last trading day.

What is Entera Bio Ltd (ENTX)'s business?

What is the price predicton of ENTX Stock?

What is Entera Bio Ltd (ENTX)'s revenue for the last quarter?

What is Entera Bio Ltd (ENTX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Entera Bio Ltd (ENTX)'s fundamentals?

How many employees does Entera Bio Ltd (ENTX). have?
